Compare Gigacloud Technology Inc (GCT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Mesoblast Limited — how do they compare? Gigacloud Technology Inc trades at $57.26 (market cap $2.02B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Gigacloud Technology Inc is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Mesoblast Limited for 15 Days on average.
| GCT | MESO | |
|---|---|---|
Market Cap | $2.02B | $1.75B |
Volume | 1,020,985 | 239,027 |
Sector | Technology | Health |
52-Week High | $57.26 | $20.96 |
52-Week Low | $25.46 | $13.19 |
Typical Hold Time | 21 Days | 15 Days |
Enterprise Value | $2.14B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $56.42, up 0.82% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with consistent earnings beats, 10.65% net margins, and 32.34% ROE. Revenue growth from $1.29B to $1.5B projected for 2026 supports valuation at 13.44 P/E. Recent news highlights institutional interest and European expansion driving optimism.
Outlook remains positive given earnings momentum and reasonable valuation, though risks include insider selling and competitive pressures. Analyst consensus favors Buy with $32.50 target, but current price exceeds consensus suggesting cautious near-term positioning may be warranted despite strong operational performance.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
